Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PDE6D | O43924 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | GCGR | P47871 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12617063 | 0.90 | HMGCR (0.46) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL17965448 | 0.88 | HMGCR (0.45) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13538 | 0.87 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10129259 | 0.87 | HMGCR (0.48) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10360 | 0.86 | HMGCR (0.48) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL12809951 | 0.86 | ABCC3 (0.44) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL5698777 | 0.86 | HMGCR (0.49) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10129222 | 0.85 | HMGCR (0.48) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL16070782 | 0.85 | HMGCR (0.45) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL27607738 | 0.84 | HMGCR (0.44) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765947-B2 | Preparation method of Rosuvastatin calcium and its intermediates | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2014-07-01 | — | — | US | disclosed |
| US-8653265-B2 | Preparation method of rosuvastatin calcium and its intermediates | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2014-02-18 | — | — | US | disclosed |
| US-20130197224-A1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-08-01 | — | — | US | disclosed |
| EP-2423195-A1 | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof | LEK Pharmaceuticals d.d. (SI) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |
| US-20110124864-A1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124864-A1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CETP, HMGCR, MTTP | HMGCR 2/4885ALDH1A1 2072/4885CYP3A4 218/4885 |
| US-20130197224-A1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CETP, HMGCR, MTTP | HMGCR 2/4885ALDH1A1 2072/4885CYP3A4 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.